达克替尼治疗 - 阳性非小细胞肺癌患者皮肤不良反应的疗效：ARCHER 1050 的分析。
Efficacy in patients with -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: analyses from ARCHER 1050.
机构信息
Second Department of Thoracic Oncology, Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, Chengdu, 610000, China.
出版信息
Future Oncol. 2024;20(37):2971-2982. doi: 10.1080/14796694.2024.2404762. Epub 2024 Oct 3.
We investigated association between skin adverse events (AEs) and efficacy with dacomitinib in patients with -positive non-small-cell lung cancer (NSCLC). analyses from ARCHER 1050 evaluated efficacy in patients who did and did not experience grade ≥2 skin AEs with dacomitinib. Landmark analyses were performed at 3 and 6 months. In patients who had skin AEs (72.2%) vs. those who did not (27.7%), median progression-free survival was 16.0 vs. 9.2 months, median overall survival (OS) was 37.7 vs. 21.6 months, and objective response rate was 80.2 vs. 61.5%; OS was improved at 3 and 6 months landmark analyses. Presence of grade ≥2 skin AEs was associated with numerically improved efficacy and represents a valuable biomarker of treatment outcome with dacomitinib in patients with advanced NSCLC. NCT01774721 (ClinicalTrials.gov).
我们研究了达可替尼与皮肤不良反应（AE）之间的相关性以及在 -阳性非小细胞肺癌（NSCLC）患者中的疗效。ARCHER 1050 的分析评估了达可替尼治疗有和无≥2 级皮肤 AE 的患者的疗效。在 3 个月和 6 个月时进行了里程碑分析。在有皮肤 AE 的患者（72.2%）与无皮肤 AE 的患者（27.7%）相比，中位无进展生存期分别为 16.0 个月和 9.2 个月，中位总生存期（OS）分别为 37.7 个月和 21.6 个月，客观缓解率分别为 80.2%和 61.5%；在 3 个月和 6 个月的里程碑分析中，OS 得到改善。存在≥2 级皮肤 AE 与疗效的数值改善相关，代表了晚期 NSCLC 患者使用达可替尼治疗的有价值的治疗结果生物标志物。NCT01774721（ClinicalTrials.gov）。
Zotero 插件